Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the United St
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company and minority stakeholder in BT
Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%
Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,7
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced publication
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, announced today that based o
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter Into a Definitive Strategic Development Agreement
Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software Suite to Enable Revolutionary Treatments of Epilepsy and Brain Tumors WAKEFIELD, MA, Jan. 0
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical's vision of revolutionizing treatment options in neurosurgery, oncology, and a wide spectrum of other clinical s
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"
Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical WAKEFIELD, MA, Oct. 26, 2022 (GLOB
Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited poten
Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
WAKEFIELD, MA / ACCESSWIRE / September 13, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today updated shareholders on recent progress by
Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox
WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defens
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
WAKEFIELD, MA / ACCESSWIRE / July 22, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the Company's Brilacidin p
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
WAKEFIELD, MA / ACCESSWIRE / June 23, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported that Brilacidin, the Company's defensin
Innovation Pharma acquires minority stake in Israeli med-tech company Squalus
Innovation Pharmaceuticals (OTCQB:IPIX) said it acquired a minority stake in Israeli medical device maker Squalus Medical. IPIX said Squalus is developing a novel laser-based thermal ablation technolo
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology
Innovation Pharmaceuticals acquires a minority ownershipSqualus has invented and is developing a leading-edge image guided surgical laser platform for treating previously inoperable cases of epilepsy
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Compan
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on th
Innovation Pharmaceuticals Provides Brilacidin Program Update
WAKEFIELD, MA / ACCESSWIRE / November 18, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on clinical development p
No Data